Publications by authors named "Denis Volodin"
Background External beam radiotherapy for resistant retinoblastoma is now seen as a last resort to saving the eye because of the risk of severe side effects: secondary cancers and cosmetic problems of orbital bone growth retardation. To reduce such complications, treatment modalities have shifted towards new radiation therapy techniques. No information on single fraction Gamma Knife® radiosurgery (GKRS) for intraocular retinoblastoma exists.
View Article and Find Full Text PDFArticle Synopsis
- The study aims to assess how presenting features, tumor size, and treatment methods impact the risk of metastatic death in patients with advanced intraocular retinoblastoma (RB) based on a large international data set.
- A total of 1,841 patients were evaluated, categorized according to AJCC standards for tumor size, with treatment options including enucleation and various chemotherapy approaches leading to different survival outcomes.
- Results showed a significant correlation between tumor category and mortality risk, with higher risks linked to larger tumor stages (cT3) and specific complications, while primary enucleation yielded the best survival rates compared to other treatment modalities.
Purpose: To determine the value of clinical features for advanced intraocular retinoblastoma as defined by the eighth edition of the American Joint Committee on Cancer (AJCC) cT3 category and AJCC Ophthalmic Oncology Task Force (OOTF) Size Groups to predict the high-risk pathologic features.
Design: International, multicenter, registry-based retrospective case series.
Participants: Eighteen ophthalmic oncology centers from 13 countries over 6 continents shared evaluations of 942 eyes enucleated as primary treatment for AJCC cT3 and, for comparison, cT2 retinoblastoma.
Aim: To investigate whether the American Joint Committee on Cancer (AJCC) clinical category cT2b needs to be subclassified by the type and distribution of retinoblastoma (RB) seeding.
Methods: Multicentre, international registry-based data were collected from RB centres enrolled between January 2001 and December 2013. 1054 RB eyes with vitreous or subretinal seeds from 18 ophthalmic oncology centres, in 13 countries within six continents were analysed.